Vergelijking
LL-37 vs. Melanotan II
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
597562-32-8
121062-08-6
Molecuulmassa
4493.33 g/mol
1024.18 g/mol
Halfwaardetijd
geen gegevens
1 h
Sequentie
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Werkingsmechanisme
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Bewijsbasis
Hoogste bewijs
Humane studie
Humane studie
Studies
4
9
waarvan bij mensen
1
5
Geregistreerde effecten
4
4
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
0
6
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between LL-37 and Melanotan II?
- LL-37 is classified as "Onderzoek (overig)", while Melanotan II is classified as "Onderzoek (overig)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Melanotan II?
- The highest available evidence level is "Humane studie" for LL-37 and "Humane studie" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Melanotan II in Germany and the United States?
- Duitsland: LL-37 — Alleen onderzoek, Melanotan II — Niet goedgekeurd. Verenigde Staten: LL-37 — Alleen onderzoek, Melanotan II — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.